Q BioMed Inc. Strengthens Advisory Board

Company welcomes Dr. Susan E Quaggin, Dr. George Nikopoulos and Dr. MaryJane Rafii to its list of strategic advisors

Nov 12, 2015, 12:14 ET from Q BioMed Inc

NEW YORK, November 12, 2015 /PRNewswire/ --

Q BioMed Inc. (OTC Pink: QBIO), a biotechnology acceleration company, is pleased to announce the addition of Mannin Research Inc. executives, Dr. Susan E Quaggin and Dr. George Nikopoulos and through our strategic advisory group Wombat Capital, a new ophthalmology specialist advisor, Dr. MaryJane Rafii.

Dr. MaryJane Rafii (PHD) 

Dr. Rafii is currently Senior Director, Corporate Development and Strategy, Ora Inc. Ora is the world's leading independent, full-service ophthalmic drug and device development firm with offices in the United States and Japan. Over the past 30 years, Ora has played a key role in over 40 regulatory approvals in the US. Dr Rafii is also the Co-founder and a Board Member of JADE Therapeutics, an ophthalmology focused company based in Salt Lake City, UT. Jade Therapeutics' idea was based on unmet medical need in the ocular disease area.  

Dr. Rafii previously served as Early Asset Lead at Pfizer Worldwide Research and Development in New York for all Ophthalmology, Neuroscience and Pain assets and also as a Medical Lead for the Specialty Care Business Unit (SCBU) - Ophthalmology and Neuroscience. Prior to Pfizer, she served as Chief Medical Officer for Fovea Pharmaceuticals in Paris, which was successfully acquired by Sanofi Aventis in 2009.

Dr Rafii has held executive roles at Bioenvision Inc., an oncology focused publicly traded company acquired by Genzyme, as well as the Ludwig Institute for Cancer Research (LICR) and LifeCycle Pharma all based in New York City.  Dr Rafii has a PhD from Cardiff University in Ophthalmology and a Master of Science in Biochemistry, Stanford University, Palo Alto, CA, and obtained her Bachelor of Science in Molecular Biology, University of Southern California, Los Angeles, CA.

Dr. Susan E. Quaggin, Chief Scientific Officer, Mannin Research Inc. 

Susan Quaggin, MD graduated from the Faculty of Medicine at the University of Toronto in 1988 and received her specialty degree in Internal Medicine in 1992. She completed her sub-specialty training in Nephrology in 1993 at U of T and did a post-doctoral fellowship at Yale University where she studied the genetic basis of kidney development.

In 1997, she returned to Toronto to do a second post-doctoral fellowship in mouse genetics in the laboratory of Janet Rossant. From 1997 until 2012, she was at the University of Toronto where she was a Senior Scientist at the Samuel Lunenfeld Research Institute, a practicing Nephrologist at St. Michael's Hospital and the Gabor-Zellerman Professor in Renal Medicine.

Dr. Quaggin has served as an elected councilor of the American Society for Clinical Investigation (ASCI), as a member of the ISN executive Council, was elected to the American Association of Physicians (AAP) in 2013 and is an elected councilor of the American Society of Nephrology (2015-2022). She received the Kidney Foundation of Canada 2009 Award for Research, a Finnish Distinguished Professorship in 2012 and the Alfred Newton Richards Award for Basic Science from the International Society of Nephrology in 2013. In addition, Dr. Quaggin sits on the editorial boards of several journals, and has organized a number of international renal and vascular meetings.

In January 2013, Dr. Quaggin joined Northwestern University Feinberg School of Medicine as the Charles Horace Mayo Professor of Medicine, where she serves as the director of the Feinberg Cardiovascular Research Institute (FCVRI) and chief of the Division of Nephrology and Hypertension.

Dr. Quaggin's research program focuses on genetic pathways required to establish and maintain the integrity of microvascular beds including the glomerular filtration barrier - a highly selective filter that separates the blood from the urinary space. To understand the pathways and interactions between perivascular cells and the endothelium, her research team has developed a number of genetic models that permit cell and time-specific manipulation of gene expression.


Chief Executive Officer & President Mannin Research Inc. 

Dr. Nikopoulos has worked with and advised a number of biotechnology, pharmaceutical and med-tech companies in addressing their pre-market, start-up and early stage commercialization programs. Dr. Nikopoulos' expertise includes translating complex technologies and innovations into strategies for commercialization, market research, and business development as well as pre-clinical toxicology study design, and research and development.

Dr. Nikopoulos received his BSc. from the University of Western Ontario, his PhD in Biochemistry and Molecular Biology from the University of Maine, where he received a fellowship from the American Heart Association, and an MBA from the Ivey School of Business, where he was the recipient of the Fairfax Award.

About Q BioMed Inc. 

Q BioMed Inc. "Q" is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need‏.

Forward-Looking Statements: 

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.


Denis Corin
Q BioMed Inc.